Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace
Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy biotech from the wider industry trend of layoffs.
Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy biotech from the wider industry trend of layoffs.
